Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in J Invest Dermatol

Retrieve available abstracts of 104 articles:
HTML format
Text format



Single Articles


    June 2017
  1. VAN TUYN J, Jaber-Hijazi F, MacKenzie D, Cole JJ, et al
    Oncogene-Expressing Senescent Melanocytes Upregulate Mhc Class Ii, A Candidate Melanoma Suppressor Function.
    J Invest Dermatol. 2017 Jun 21. pii: S0022-202X(17)31662.
    PubMed     Text format     Abstract available


  2. ASGARI MM, Chien AJ, Tsai AL, Fireman B, et al
    Association between lithium use and melanoma risk and mortality: A population-based study.
    J Invest Dermatol. 2017 Jun 16. pii: S0022-202X(17)31644.
    PubMed     Text format     Abstract available


  3. THEODOSAKIS N, Micevic G, Langdon CG, Ventura A, et al
    p90RSK blockade inhibits dual BRAF and MEK inhibitor-resistant melanoma by targeting protein synthesis.
    J Invest Dermatol. 2017 Jun 6. pii: S0022-202X(17)31603.
    PubMed     Text format     Abstract available


    May 2017
  4. BUSTOS MA, Ono S, Marzese DM, Oyama T, et al
    MiR-200a Regulates CDK4/6 Inhibitor Effect by targeting CDK6 in Metastatic Melanoma.
    J Invest Dermatol. 2017 May 16. pii: S0022-202X(17)31528.
    PubMed     Text format     Abstract available


  5. SHI Q, Liu H, Han P, Li C, et al
    Genetic Variants in WNT2B and BTRC Predict Melanoma Survival.
    J Invest Dermatol. 2017 May 9. pii: S0022-202X(17)31489.
    PubMed     Text format     Abstract available


  6. LEITER U, Keim U, Eigentler T, Katalinic A, et al
    Incidence, Mortality and Trends of Non-Melanoma Skin Cancer in Germany.
    J Invest Dermatol. 2017 May 6. pii: S0022-202X(17)31482.
    PubMed     Text format     Abstract available


  7. BAUER J
    The Molecular Revolution in Cutaneous Biology: Era of Cytogenetics and Copy Number Analysis.
    J Invest Dermatol. 2017;137:e57-e59.
    PubMed     Text format     Abstract available


    April 2017
  8. FANG S, Wang Y, Dang Y, Gagel A, et al
    Association between body mass index, C-reactive protein levels, and melanoma patient outcomes.
    J Invest Dermatol. 2017 Apr 22. pii: S0022-202X(17)31423.
    PubMed     Text format    


  9. KIM SH, Li M, Trousil S, Zhang Y, et al
    Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma.
    J Invest Dermatol. 2017 Apr 19. pii: S0022-202X(17)31420.
    PubMed     Text format     Abstract available


  10. SFECCI A, Dupuy A, Dinulescu M, Droitcourt C, et al
    Do the Side Effects of BRAF Inhibitors Mimic RASopathies?
    J Invest Dermatol. 2017;137:805-809.
    PubMed     Text format     Abstract available


    February 2017
  11. PUIG-BUTILLE JA, Vinyals A, Ferreres JR, Aguilera P, et al
    AURORA A overexpression (AURKA) is driven by FOXM1 and MAPK/ERK activation in melanoma cells harbouring BRAF or NRAS mutations: Impact on melanoma prognosis and therapy.
    J Invest Dermatol. 2017 Feb 7. pii: S0022-202X(17)30115.
    PubMed     Text format     Abstract available


  12. ZHOU Y, Tripathi SV, Rosman I, Ma J, et al
    Noninvasive Determination of Melanoma Depth using a Handheld Photoacoustic Probe.
    J Invest Dermatol. 2017 Feb 2. pii: S0022-202X(17)30104.
    PubMed     Text format    


    January 2017
  13. TROUSIL S, Chen S, Mu C, Shaw FM, et al
    Phenformin enhances the efficacy of ERK inhibition in NF1-mutant melanoma.
    J Invest Dermatol. 2017 Jan 28. pii: S0022-202X(17)30052.
    PubMed     Text format     Abstract available


  14. TSAO H, Fukunaga-Kalabis M, Herlyn M
    Recent Advances in Melanoma and Melanocyte Biology.
    J Invest Dermatol. 2017 Jan 12. pii: S0022-202X(16)32640.
    PubMed     Text format    


    December 2016
  15. ROOS L, Sandling JK, Bell CG, Glass D, et al
    Higher Naevus Count Exhibits A Distinct DNA Methylation Signature in Healthy Human Skin: Implications for Melanoma.
    J Invest Dermatol. 2016 Dec 16. pii: S0022-202X(16)32787.
    PubMed     Text format     Abstract available


  16. KAWAKAMI A, Fisher DE
    Bioinformatic Analysis of Gene Expression for Melanoma Treatment.
    J Invest Dermatol. 2016;136:2342-2344.
    PubMed     Text format     Abstract available


    November 2016
  17. MELAMED RD, Aydin IT, Rajan GS, Phelps R, et al
    Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma.
    J Invest Dermatol. 2016 Nov 24. pii: S0022-202X(16)32663.
    PubMed     Text format     Abstract available


  18. CHIANG NY, Peng YM, Juang HH, Chen TC, et al
    GPR56/ADGRG1 activation promotes melanoma cell migration via NTF dissociation and CTF-mediated Galpha12/13/RhoA signaling.
    J Invest Dermatol. 2016 Nov 3. pii: S0022-202X(16)32618.
    PubMed     Text format     Abstract available


    October 2016
  19. KOHLI JS, Tolomio E, Frigerio S, Maurichi A, et al
    Common Delayed Senescence of Melanocytes from Multiple Primary Melanoma Patients.
    J Invest Dermatol. 2016 Oct 28. pii: S0022-202X(16)32610.
    PubMed     Text format    


    September 2016
  20. LUCARINI V, Buccione C, Ziccheddu G, Peschiaroli F, et al
    Combining Type I Interferons and 5-Aza-2'-Deoxycitidine to improve anti-tumor response against melanoma.
    J Invest Dermatol. 2016 Sep 10. pii: S0022-202X(16)32368.
    PubMed     Text format     Abstract available


  21. RUNGER TM
    Mechanisms of Melanoma Promotion by Ultraviolet Radiation.
    J Invest Dermatol. 2016;136:1751-2.
    PubMed     Text format     Abstract available


    August 2016
  22. FANG S, Vaysse A, Brossard M, Wang Y, et al
    Melanoma expression genes identified through genome-wide association study of Breslow tumor thickness.
    J Invest Dermatol. 2016 Aug 6. pii: S0022-202X(16)32250.
    PubMed     Text format    


  23. MATHEIS F, Heppt MV, Graf SA, Duwell P, et al
    A bifunctional approach of immunostimulation and uPAR inhibition shows potent antitumor activity in melanoma.
    J Invest Dermatol. 2016 Aug 3. pii: S0022-202X(16)32234.
    PubMed     Text format     Abstract available


    July 2016
  24. SHI J, Zhou W, Zhu B, Hyland PL, et al
    Rare germline copy number variations and disease susceptibility in familial melanoma.
    J Invest Dermatol. 2016 Jul 28. pii: S0022-202X(16)32229.
    PubMed     Text format     Abstract available


  25. KUMAR D, Kumar S, Gorain M, Tomar D, et al
    Notch1-MAPK Signaling Axis Regulates CD133+ Cancer Stem Cell-Mediated Melanoma Growth and Angiogenesis.
    J Invest Dermatol. 2016 Jul 28. pii: S0022-202X(16)32232.
    PubMed     Text format     Abstract available


  26. PAVLOVA O, Fraitag S, Hohl D
    5-hydroxymethylcytosine expression in proliferative nodules arising within congenital nevi allows differentiation from malignant melanoma.
    J Invest Dermatol. 2016 Jul 22. pii: S0022-202X(16)32124.
    PubMed     Text format     Abstract available


  27. WEIDE B, Schafer T, Martens A, Kuzkina A, et al
    High GDF-15 serum levels independently correlate with poorer overall survival of tumor-free stage III and unresectable stage IV melanoma patients.
    J Invest Dermatol. 2016 Jul 22. pii: S0022-202X(16)32125.
    PubMed     Text format     Abstract available


  28. WANG JY, Jin L, Yan XG, Sherwin S, et al
    Reactive oxygen species dictate the apoptotic response of melanoma cells to TH588.
    J Invest Dermatol. 2016 Jul 14. pii: S0022-202X(16)32104.
    PubMed     Text format     Abstract available


  29. GULATI N, Garcet S, Fuentes-Duculan J, Gilleaudeau P, et al
    Molecular profiling of immune activation associated with regression of melanoma metastases induced by diphencyprone.
    J Invest Dermatol. 2016 Jul 1. pii: S0022-202X(16)32084.
    PubMed     Text format    


    June 2016
  30. PIETROBONO S, Morandi A, Gagliardi S, Gerlini G, et al
    Downregulation of SOX2 underlies the inhibitory effects of the triphenylmethane gentian violet on melanoma cell self-renewal and survival.
    J Invest Dermatol. 2016 Jun 29. pii: S0022-202X(16)32083.
    PubMed     Text format     Abstract available


  31. GIMOTTY PA, Shore R, Lozon N, Whitlock J, et al
    Miscoding of melanoma thickness in SEER: Research and clinical implications.
    J Invest Dermatol. 2016 Jun 25. pii: S0022-202X(16)31960.
    PubMed     Text format    


  32. GREVELING K, Wakkee M, Nijsten T, van den Bos RR, et al
    Epidemiology of lentigo maligna and lentigo maligna melanoma in the Netherlands, 1989 - 2013.
    J Invest Dermatol. 2016 Jun 24. pii: S0022-202X(16)31365.
    PubMed     Text format     Abstract available


  33. LAUSS M, Nsengimana J, Staaf J, Newton-Bishop J, et al
    Consensus of melanoma gene expression subtypes converges on biological entities.
    J Invest Dermatol. 2016 Jun 23. pii: S0022-202X(16)31363.
    PubMed     Text format    


  34. SALTARI A, Truzzi F, Quadri M, Lotti R, et al
    CD271 downregulation promotes melanoma progression and invasion in 3-dimensional models and in zebrafish.
    J Invest Dermatol. 2016 Jun 17. pii: S0022-202X(16)31351.
    PubMed     Text format     Abstract available


  35. CASULA M, Colombino M, Manca A, Caraco C, et al
    Low levels of genetic heterogeneity in matched lymph node metastases from melanoma patients.
    J Invest Dermatol. 2016 Jun 2. pii: S0022-202X(16)31332.
    PubMed     Text format    


    May 2016
  36. NAJITA JS, Swetter SM, Geller AC, Gershenwald JE, et al
    Sex differences in age at primary melanoma diagnosis in a population-based analysis (US Surveillance, Epidemiology, and End Results, 2005-2011).
    J Invest Dermatol. 2016 May 29. pii: S0022-202X(16)31263.
    PubMed     Text format    


  37. POSCH C, Sanlorenzo M, Vujic I, Oses-Prieto JA, et al
    Phospho-proteomic analyses of NRAS(G12) and NRAS(Q61) mutant melanocytes reveal increased CK2alpha kinase levels in NRAS(Q61) mutant cells.
    J Invest Dermatol. 2016 May 29. pii: S0022-202X(16)31261.
    PubMed     Text format     Abstract available


  38. WHITEMAN DC, Green AC, Olsen CM
    The relentless rise in the incidence of melanoma in susceptible Australians - Response.
    J Invest Dermatol. 2016 May 25. pii: S0022-202X(16)31259.
    PubMed     Text format    


  39. HALABAN R, Krauthammer M
    RASopathy Gene Mutations in Melanoma.
    J Invest Dermatol. 2016 May 25. pii: S0022-202X(16)31257.
    PubMed     Text format     Abstract available


  40. CZARNECKI D
    The relentless rise in the incidence of melanoma in susceptible Australians.
    J Invest Dermatol. 2016 May 25. pii: S0022-202X(16)31151.
    PubMed     Text format    


  41. YELAMOS O, Merkel EA, Sholl LM, Zhang B, et al
    Non-overlapping Clinical and Mutational Patterns in Melanomas from the Female Genital Tract and Atypical Genital Nevi.
    J Invest Dermatol. 2016 May 21. pii: S0022-202X(16)31256.
    PubMed     Text format     Abstract available


  42. KAMENISCH Y, Baban TS, Schuller W, von Thaler AK, et al
    UVA-irradiation induces melanoma invasion via enhanced Warburg effect.
    J Invest Dermatol. 2016 May 13. pii: S0022-202X(16)31243.
    PubMed     Text format     Abstract available


  43. POSCH C, Vujic I, Monshi B, Sanlorenzo M, et al
    Searching for the Chokehold of NRAS Mutant Melanoma.
    J Invest Dermatol. 2016 May 7. pii: S0022-202X(16)30881.
    PubMed     Text format     Abstract available


    April 2016
  44. VAN DE NES J, Wrede K, Ringelstein A, Stiller M, et al
    Diagnosing a primary leptomeningeal melanoma by gene mutation signature.
    J Invest Dermatol. 2016 Apr 6. pii: S0022-202X(16)31023.
    PubMed     Text format    


    March 2016
  45. YOULDEN DR, Baade PD, Soyer HP, Youl PH, et al
    Ten-year survival after multiple invasive melanomas is worse than after a single melanoma: a population-based study.
    J Invest Dermatol. 2016 Mar 23. pii: S0022-202X(16)30930.
    PubMed     Text format     Abstract available


  46. BEAUMONT KA, Hill DS, Daignault SM, Lui GY, et al
    Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells.
    J Invest Dermatol. 2016 Mar 9. pii: S0022-202X(16)30862.
    PubMed     Text format     Abstract available


  47. RAMBOW F, Bechadergue A, Luciani F, Gros G, et al
    Regulation of melanoma progression through the TCF4/miR-125b/NEDD9 cascade.
    J Invest Dermatol. 2016 Mar 8. pii: S0022-202X(16)30857.
    PubMed     Text format     Abstract available


  48. KYPREOU KP, Stefanaki I, Antonopoulou K, Karagianni F, et al
    Prediction of Melanoma Risk in a Southern European Population Based on a Weighted Genetic Risk Score.
    J Invest Dermatol. 2016;136:690-695.
    PubMed     Text format     Abstract available


    February 2016
  49. WHITEMAN DC, Green AC, Olsen CM
    The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations to 2031.
    J Invest Dermatol. 2016 Feb 19. pii: S0022-202X(16)00488.
    PubMed     Text format     Abstract available


  50. GE R, Liu L, Dai W, Zhang W, et al
    XPA promotes autophagy to facilitate cisplatin resistance in melanoma cells through the activation of PARP1.
    J Invest Dermatol. 2016 Feb 12. pii: S0022-202X(16)00468.
    PubMed     Text format     Abstract available


  51. ROH MR, Gupta S, Park KH, Chung KY, et al
    Promoter Methylation of PTEN is a Significant Prognostic Factor in Melanoma Survival.
    J Invest Dermatol. 2016 Feb 5. pii: S0022-202X(16)00458.
    PubMed     Text format     Abstract available


  52. LANDSBERG J, Tuting T, Barnhill RL, Lugassy C, et al
    The Role of Neutrophilic Inflammation, Angiotropism, and Pericytic Mimicry in Melanoma Progression and Metastasis.
    J Invest Dermatol. 2016;136:372-7.
    PubMed     Text format     Abstract available


  53. SZEGEZDI E, Leverkus M
    Guiding the Killer and Bringing in Accomplices: Bispecific Antibody Treatment for Malignant Melanoma.
    J Invest Dermatol. 2016;136:362-4.
    PubMed     Text format     Abstract available


  54. HE Y, Hendriks D, van Ginkel R, Samplonius D, et al
    Melanoma-Directed Activation of Apoptosis Using a Bispecific Antibody Directed at MCSP and TRAIL Receptor-2/Death Receptor-5.
    J Invest Dermatol. 2016;136:541-544.
    PubMed     Text format    


  55. ZHANG K, Wong P, Salvaggio C, Salhi A, et al
    Synchronized Targeting of Notch and ERBB Signaling Suppresses Melanoma Tumor Growth through Inhibition of Notch1 and ERBB3.
    J Invest Dermatol. 2016;136:464-472.
    PubMed     Text format     Abstract available


  56. VU HL, Rosenbaum S, Capparelli C, Purwin TJ, et al
    MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.
    J Invest Dermatol. 2016;136:453-463.
    PubMed     Text format     Abstract available


    January 2016
  57. GUO S, Guo W, Li S, Dai W, et al
    Serum miR-16: a potential biomarker for predicting melanoma prognosis.
    J Invest Dermatol. 2016 Jan 29. pii: S0022-202X(16)00365.
    PubMed     Text format    


  58. PUUJALKA E, Heinz M, Hoesel B, Friedl P, et al
    Opposing roles of JNK and p38 in lymphangiogenesis in melanoma.
    J Invest Dermatol. 2016 Jan 29. pii: S0022-202X(16)00374.
    PubMed     Text format     Abstract available


  59. JACQUELOT N, Roberti MP, Enot DP, Rusakiewicz S, et al
    Immunophenotyping of stage III melanoma reveals parameters associated with patient prognosis.
    J Invest Dermatol. 2016 Jan 29. pii: S0022-202X(16)00366.
    PubMed     Text format     Abstract available


  60. TAYLOR NJ, Handorf EA, Mitra N, Avril MF, et al
    Phenotypic and histopathological tumor characteristics according to CDKN2A mutation status among affected members of melanoma families.
    J Invest Dermatol. 2016 Jan 28. pii: S0022-202X(16)00355.
    PubMed     Text format    


  61. HACKER E, Olsen CM, Kvaskoff M, Pandeya N, et al
    Histologic and phenotypic factors and MC1R status associated with BRAF, BRAF and NRAS mutations in a community-based sample of 414 cutaneous melanomas.
    J Invest Dermatol. 2016 Jan 22. pii: S0022-202X(16)00351.
    PubMed     Text format     Abstract available


  62. FAN Y, Lee S, Wu G, Easton J, et al
    Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi.
    J Invest Dermatol. 2016;136:339-42.
    PubMed     Text format    


  63. UGUEN A, Talagas M, Marcorelles P, De Braekeleer M, et al
    BRAFV600E and NRASQ61R Homogeneity in Melanoma Tumors.
    J Invest Dermatol. 2016;136:337-8.
    PubMed     Text format    


  64. PATHRIA G, Garg B, Wagner C, Garg K, et al
    RanBP3 Regulates Melanoma Cell Proliferation via Selective Control of Nuclear Export.
    J Invest Dermatol. 2016;136:264-74.
    PubMed     Text format     Abstract available


  65. INOZUME T, Yaguchi T, Furuta J, Harada K, et al
    Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
    J Invest Dermatol. 2016;136:255-63.
    PubMed     Text format     Abstract available


  66. JAYAWARDANA K, Schramm SJ, Tembe V, Mueller S, et al
    Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma.
    J Invest Dermatol. 2016;136:245-54.
    PubMed     Text format     Abstract available


  67. NAKAHARA T, Oba J, Shimomura C, Kido-Nakahara M, et al
    Early Tumor-Infiltrating Dendritic Cells Change their Characteristics Drastically in Association with Murine Melanoma Progression.
    J Invest Dermatol. 2016;136:146-53.
    PubMed     Text format     Abstract available


  68. MAHNKE K, Enk AH
    TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention.
    J Invest Dermatol. 2016;136:9-11.
    PubMed     Text format     Abstract available


    December 2015
  69. BUZAS K, Marton A, Vizler C, Gyukity-Sebestyen E, et al
    Bacterial sepsis increases survival in metastatic melanoma: Chlamydophila pneumoniae induces macrophage polarization and tumor regression.
    J Invest Dermatol. 2015 Dec 29. pii: S0022-202X(15)00328.
    PubMed     Text format    


  70. GEORGE J, Nihal M, Singh CK, Zhong W, et al
    Pro-proliferative function of mitochondrial sirtuin deacetylase SIRT3 in human melanoma.
    J Invest Dermatol. 2015 Dec 29. pii: S0022-202X(15)00322.
    PubMed     Text format     Abstract available


  71. CHANG GA, Polsky D
    Mutational Heterogeneity in Melanoma: An Inconvenient Truth.
    J Invest Dermatol. 2015;135:2913-8.
    PubMed     Text format     Abstract available


  72. FEDORENKO IV, Wargo JA, Flaherty KT, Messina JL, et al
    BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape.
    J Invest Dermatol. 2015;135:3115-24.
    PubMed     Text format     Abstract available


  73. MENON DR, Schaider H
    Microenvironment-Driven Resistance to BRAF Inhibition Comes of Age.
    J Invest Dermatol. 2015;135:2923-5.
    PubMed     Text format     Abstract available


    November 2015
  74. WHITEMAN DC, Olsen CM
    Melanoma Incidence and Lethality Is Increased Following Solid Organ Transplantation.
    J Invest Dermatol. 2015;135:2560-2.
    PubMed     Text format     Abstract available


    October 2015
  75. INOZUME T, Yaguchi T, Furuta J, Harada K, et al
    Melanoma Cells Control Anti-Melanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
    J Invest Dermatol. 2015 Oct 12. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  76. PATHRIA G, Garg B, Wagner C, Garg K, et al
    RanBP3 Regulates Melanoma Cell Proliferation via Selective Control of Nuclear Export.
    J Invest Dermatol. 2015 Oct 8. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  77. CHEN HY, Villanueva J
    Playing Polo-Like Kinase in NRAS-Mutant Melanoma.
    J Invest Dermatol. 2015;135:2352-5.
    PubMed     Text format     Abstract available


  78. ALDAHAN AS, Mlacker S, Shah VV, Samarkandy S, et al
    Cells to Surgery Quiz: October 2015.
    J Invest Dermatol. 2015;135:e18.
    PubMed     Text format    


    September 2015
  79. FAN Y, Lee S, Wu G, Easton J, et al
    Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi.
    J Invest Dermatol. 2015 Sep 24. doi: 10.1038/jid.2015.
    PubMed     Text format    


  80. NAKAHARA T, Oba J, Shimomura C, Kido-Nakahara M, et al
    Early Tumor-Infiltrating Dendritic Cells Change their Characteristics Drastically in Association with Murine Melanoma Progression.
    J Invest Dermatol. 2015 Sep 15. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  81. JAYAWARDANA K, Schramm SJ, Tembe V, Mueller S, et al
    Identification, Review and Systematic Cross-Validation of MicroRNA Prognostic Signatures in Metastatic Melanoma.
    J Invest Dermatol. 2015 Sep 9. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  82. UGUEN A, Talagas M, Marcorelles P, De Braekeleer M, et al
    BRAFV600E and NRASQ61R Homogeneity in Melanoma Tumors.
    J Invest Dermatol. 2015 Sep 3. doi: 10.1038/jid.2015.
    PubMed     Text format    


  83. WEI E, Miteva M
    September 2015 Snapshot Dx Quiz: Linking Science to Patient Care.
    J Invest Dermatol. 2015;135:e32.
    PubMed     Text format    


    August 2015
  84. KEEGAN TH, Swetter SM, Tao L, Sunwoo JB, et al
    Tumor Ulceration does not Fully Explain Sex Disparities in Melanoma Survival among Adolescents and Young Adults.
    J Invest Dermatol. 2015 Aug 19. doi: 10.1038/jid.2015.
    PubMed     Text format    


  85. ROBBINS HA, Clarke CA, Arron ST, Tatalovich Z, et al
    Melanoma Risk and Survival Among Organ Transplant Recipients.
    J Invest Dermatol. 2015 Aug 13. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  86. HO AW, Tsao H
    Targeted Therapies in Melanoma: Translational Research at Its Finest.
    J Invest Dermatol. 2015;135:1929-33.
    PubMed     Text format    


    July 2015
  87. TANESE K, Hashimoto Y, Berkova Z, Wang Y, et al
    Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-gamma.
    J Invest Dermatol. 2015 Jul 16. doi: 10.1038/jid.2015.
    PubMed     Text format    


  88. HUTCHENREUTHER J, Vincent KM, Carter DE, Postovit LM, et al
    CCN2 Expression By Tumor Stroma is Required for Melanoma Metastasis.
    J Invest Dermatol. 2015 Jul 13. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  89. QUAST SA, Steinhorst K, Plotz M, Eberle J, et al
    Sensitization of Melanoma Cells for Death Ligand Trail is Based on Cell Cycle Arrest, Ros Production and Activation of Proapoptotic Bcl-2 Proteins.
    J Invest Dermatol. 2015 Jul 2. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  90. VAN DEN REEK JM, Kievit W, Gniadecki R, Goeman JJ, et al
    Drug Survival Studies in Dermatology:Principles, Purposes, and Pitfalls.
    J Invest Dermatol. 2015;135:e34.
    PubMed     Text format    


  91. JI Z, Erin Chen Y, Kumar R, Taylor M, et al
    MITF Modulates Therapeutic Resistance through EGFR Signaling.
    J Invest Dermatol. 2015;135:1863-72.
    PubMed     Text format     Abstract available


    June 2015
  92. MAIRHOFER DG, Ortner D, Tripp CH, Schaffenrath S, et al
    Impaired gp100-Specific CD8 T Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma Model.
    J Invest Dermatol. 2015 Jun 29. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  93. RIVEIRO-FALKENBACH E, Villanueva CA, Garrido MC, Ruano Y, et al
    Intra- and Inter-tumoral Homogeneity of BRAF Mutations in Melanoma Tumors.
    J Invest Dermatol. 2015 Jun 17. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  94. TANESE K, Hashimoto Y, Berkova Z, Wang Y, et al
    Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-gamma.
    J Invest Dermatol. 2015 Jun 3. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  95. PHADKE M, Gibney GT, Rich CJ, Fedorenko IV, et al
    XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation.
    J Invest Dermatol. 2015 Jun 3. doi: 10.1038/jid.2015.
    PubMed     Text format    


  96. HANDOKO HY, Rodero MP, Muller HK, Khosrotehrani K, et al
    Lack of Evidence from a Transgenic Mouse Model that the Activation and Migration of Melanocytes to the Epidermis after Neonatal UVR Enhances Melanoma Development.
    J Invest Dermatol. 2015 Jun 2. doi: 10.1038/jid.2015.
    PubMed     Text format    


  97. WIEDER SY, Serasinghe MN, Sung JC, Choi DC, et al
    Activation of The Mitochondrial Fragmentation Protein Drp1 Correlates with Braf Melanoma.
    J Invest Dermatol. 2015 Jun 1. doi: 10.1038/jid.2015.
    PubMed     Text format    


    May 2015
  98. LESSARD L, Liu M, Marzese DM, Wang H, et al
    The CASC15 Long Intergenic Non-Coding RNA Locus is Involved in Melanoma Progression and Phenotype-Switching.
    J Invest Dermatol. 2015 May 27. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  99. POSCH C, Cholewa BD, Vujic I, Sanlorenzo M, et al
    Combined Inhibition of MEK and Plk1 has Synergistic Anti-Tumor Activity in NRAS Mutant Melanoma.
    J Invest Dermatol. 2015 May 27. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


    April 2015
  100. KHALIFIAN S, Raimondi G, Brandacher G
    The use of luminex assays to measure cytokines.
    J Invest Dermatol. 2015;135:e31.
    PubMed     Text format    


  101. SIMMONS BJ, Bray FN, Falto-Aizpurua L, Alsaidan M, et al
    Cells to surgery quiz: April 2015.
    J Invest Dermatol. 2015;135:e12.
    PubMed     Text format    


  102. KATIYAR SK
    Hsp90 inhibitor can inhibit UV carcinogenesis.
    J Invest Dermatol. 2015;135:945-7.
    PubMed     Text format     Abstract available


    February 2015
  103. NUGENT JS, Vince R, Raza A
    Topical Acyclothymidine Dinucleosides (aTds) Promote non-UV Mediated Endogenous Defense Mechanisms in Guinea Pig Skin.
    J Invest Dermatol. 2015 Feb 20. doi: 10.1038/jid.2015.
    PubMed     Text format    


    October 2014
  104. SINGH A, Singh A, Sand JM, Bauer SJ, et al
    Topically Applied Hsp90 Inhibitor 17AAG Inhibits Ultraviolet Radiation-Induced Cutaneous Squamous Cell Carcinomas.
    J Invest Dermatol. 2014 Oct 22. doi: 10.1038/jid.2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: